Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Clinically significant drug interactions with antacids: an update.

Ogawa R, Echizen H.

Drugs. 2011 Oct 1;71(14):1839-64. doi: 10.2165/11593990-000000000-00000. Review.

PMID:
21942976
2.

Effects of antacids on the clinical pharmacokinetics of drugs. An update.

Gugler R, Allgayer H.

Clin Pharmacokinet. 1990 Mar;18(3):210-9. Review.

PMID:
1969784
3.

Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

Maton PN, Burton ME.

Drugs. 1999 Jun;57(6):855-70. Review.

PMID:
10400401
4.

Interests of the 'artificial stomach' techniques to study antacid formulations: comparison with in vivo evaluation.

Vatier J, Célice-Pingaud C, Farinotti R.

Fundam Clin Pharmacol. 1998;12(6):573-83. Review.

PMID:
9818289
5.

Drug-drug interaction profiles of proton pump inhibitors.

Ogawa R, Echizen H.

Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000. Review.

PMID:
20608754
6.

Drug interactions with antacids. Mechanisms and clinical significance.

Sadowski DC.

Drug Saf. 1994 Dec;11(6):395-407. Review.

PMID:
7727050
7.

pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development.

Zhang L, Wu F, Lee SC, Zhao H, Zhang L.

Clin Pharmacol Ther. 2014 Aug;96(2):266-77. doi: 10.1038/clpt.2014.87. Epub 2014 Apr 14. Review.

PMID:
24733008
8.

Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Hatlebakk JG, Berstad A.

Clin Pharmacokinet. 1996 Nov;31(5):386-406. Review.

PMID:
9118586
9.

Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.

Mandel KG, Daggy BP, Brodie DA, Jacoby HI.

Aliment Pharmacol Ther. 2000 Jun;14(6):669-90. Review.

10.

Treatment of gastroesophageal reflux disease.

Pettit M.

Pharm World Sci. 2005 Dec;27(6):432-5. Review.

PMID:
16341949
11.

Enhancement of drug absorption by antacids. An unrecognised drug interaction.

Neuvonen PJ, Kivistö KT.

Clin Pharmacokinet. 1994 Aug;27(2):120-8. Review.

PMID:
7955775
12.

New approach for the in vitro evaluation of antacids.

Vatier J, Vallot T, Vitre MT, Mignon M.

Arzneimittelforschung. 1990 Feb;40(2 Pt 1):175-9. Review.

PMID:
2185759
13.

Antacid use and reduced bioavailability of oral drugs. Case studies, overview and perspectives.

Srinivas NR.

Arzneimittelforschung. 2009;59(7):327-34. doi: 10.1055/s-0031-1296404. Review.

PMID:
19728559
14.

Gastroesophageal reflux in pregnancy: a systematic review on the benefit of raft forming agents.

Quartarone G.

Minerva Ginecol. 2013 Oct;65(5):541-9. Review.

PMID:
24096290
15.

Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.

Duong S, Leung M.

J Oncol Pharm Pract. 2011 Dec;17(4):448-52. doi: 10.1177/1078155210381794. Epub 2010 Aug 17. Review.

PMID:
20716581
16.

Drugs, diseases and altered gastric emptying.

Nimmo WS.

Clin Pharmacokinet. 1976;1(3):189-203. Review.

PMID:
797497
17.

Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.

Pisegna JR.

Crit Care Med. 2002 Jun;30(6 Suppl):S356-61. Review.

PMID:
12072661
18.

Rationale for ibuprofen co-administration with antacids: potential interaction mechanisms affecting drug absorption.

Parojcić J, Corrigan OI.

Eur J Pharm Biopharm. 2008 Jun;69(2):640-7. doi: 10.1016/j.ejpb.2008.01.001. Epub 2008 Jan 10. Review.

PMID:
18280125
19.
20.

Overview of pharmacologic agents for acid suppression in critically ill patients.

Welage LS.

Am J Health Syst Pharm. 2005 May 15;62(10 Suppl 2):S4-S10. Review.

PMID:
15905600

Supplemental Content

Support Center